Breast cancer · France · Where we start
In triple-negative breast cancer, nearly 40% of patients do not achieve a complete pathological response after chemo-immunotherapy with pembrolizumab. Recanthia reads the activity of the tumour’s master regulators to understand and predict that response: first as research services for industry from 2027, then, after validation, as clinical decision support.
Triple-negative × pembrolizumab
The question we want to answer, before treatment:
Research-stage approach: not a test available today.
01 / Where we start
Breast cancer is the most common cancer in women in France. We start with one of its hardest forms, triple-negative disease, and one specific treatment, pembrolizumab.
new breast cancer cases in France in 2023. [E2] INCa
women affected during their lifetime. [E1] Ameli
breast cancer deaths in 2023. [E2] INCa
of breast cancers are triple-negative, often in young women. Institut Curie, based on INCa
patients per year: estimated target population for chemo-immunotherapy in high-risk early triple-negative disease. [E3] HAS, 2022
without a complete pathological response after chemo-immunotherapy: 36% in the KEYNOTE-522 trial. [E4] EMA
A large share of patients do not get the expected benefit from pembrolizumab, and no validated test can tell in advance which ones.
About €64,000 additional cost per patient versus chemotherapy alone (HAS, 2023), and immune-related side effects that can be long-lasting.
Two CRCLille teams and BRCA.cRegMap, a transcriptomic platform built specifically on breast cancer.
Context figures: they describe the disease and the treatment, not the performance of Recanthia.
02 / Our offer
We start with one precise case to demonstrate the value of the approach, before extending it to other treatments and other cancers.
Step 1 · From 2027
For pharma, biotechs and CROs developing triple-negative treatments or immunotherapy combinations.
Step 2 · 2028–2030
For clinical and academic teams who want to test the signature against real-world care.
Step 3 · By 2031–2032
After clinical validation and approval: this is not a test available today.
Target timeline, conditional on results, partners and funding.
03 / Science
By studying regulatory programmes alongside available treatment and clinical data, we aim to reveal response-associated profiles and generate testable hypotheses about sensitivity and resistance.
Transcriptomic data, clinical metadata and treatment response where available.
Regulatory activity and biological programmes, compared across groups and cohorts.
Candidate mechanisms, targets, signatures and the experiments needed to test them.
Our first research programme studies response to immunotherapy in triple-negative breast cancer. Extensions to other tumour types, such as lung and head and neck cancers, and to other treatments are envisaged.
Research stage: our findings are hypotheses that require independent and functional validation. We do not publish performance figures before independent, approved results.
How we handle data and analyses · Evidence & publications
In the final pathological complete response (pCR) analysis of KEYNOTE-522, 428 of 669 patients treated with pembrolizumab plus chemotherapy reached pCR (64.0%). About 36% therefore did not reach a complete histological response at surgery — which does not mean they derived no benefit. [E4]
In France, the Haute Autorité de santé estimated the target population for this indication at about 6,640 patients per year (December 2022 estimate, not a count of treated patients). [E3]
04 / Research services
Each project is scoped around your scientific question. We are preparing our B2B research services for launch in 2027 and seeking our first pilot partners. Clinical use is a future development that will require its own validation.
Explore profiles associated with response or resistance in the available data.
Investigate biological programmes, candidate targets and potential escape mechanisms.
Estimate how often profiles of interest occur in defined cohorts, with explicit transfer assumptions.
Biological question, candidate, indication, cohorts, response criteria and expected deliverables.
Data availability and rights of use, metadata quality, power and comparability limits.
Defined analysis plan, quality control, regulatory programme analysis and clinical context.
Robust versus exploratory findings, uncertainties, confounders and mechanistic hypotheses.
Report, usable figures, scientific presentation and proposed next validations.
Tell us about your candidate, dataset or research question.
Project-based pricing — request a proposal.
05 / Roadmap
A target timeline, conditional on results, partners and funding.
Scope the offer, run first pilots, deliver reports and a reproducible analytical pipeline.
Needs Pilot clients • data • funding
Independent cohorts, biological validation and clinical context.
Needs Academic teams • cohorts • quality
Studies, analytical and clinical performance, regulatory file and quality organisation.
Needs Clinical centres • regulatory expertise
Assess clinical utility, reimbursement pathways and deployment.
Needs Dedicated funding • clinicians • market access
Clinical use, compliance, insurance and reimbursement are development goals, not achievements or guaranteed dates.
06 / Team
Cancer biology and computational analysis, brought together around therapeutic response.
Co-founder • CEO
Maxime is a cancer biology PhD researcher at the University of Lille, studying tumour plasticity and brain metastases in triple-negative breast cancer. He leads Recanthia’s business development and company structuring, while contributing to experimental validation.
Co-founder • CTO
Nathan holds a PhD from the University of Lille and developed BRCA.cRegMap during his doctoral research. His work combines transcriptomic analysis, regulatory networks and clinical data to explore tumour biology and therapeutic response.
An advisory board that brings expertise, scientific perspective and network.
Scientific Advisor
Robert-Alain contributes expertise in breast cancer biology, preclinical research and functional validation, supporting the scientific and translational direction of the project.
Scientific Advisor • Data & AI
Mohamed contributes expertise in computational methods, regulatory networks and biological data interpretation.
Scientific Advisor • Data & AI
Wajdi contributes data and AI expertise to methodological discussions and the structuring of analytical workflows.
Founding Scientific & Strategic Advisor
Erwan contributes to experimental validation, scientific discussions and the development of Recanthia’s network and communication materials, supporting the project from its formative stages.
07 / Potential impact
Better understanding treatment response could inform research priorities and, after clinical validation, support more relevant care. These are potential benefits to investigate, not demonstrated outcomes of Recanthia.
Connect molecular mechanisms, candidate response and the populations represented in the data.
Generate hypotheses about sensitivity, resistance and therapeutic gaps to guide the next experiments.
Characterise response-associated profiles and explore differences between groups, with explicit uncertainty.
Estimate the prevalence of profiles in defined cohorts to inform study design and population hypotheses.
Expected research outputs depend on available data. A cohort segment is not an established addressable market or evidence of clinical benefit.
Our clinical ambition is to help understand which patients may benefit from a treatment, and why.
Investigate whether molecular profiles could improve the assessment of expected treatment benefit.
Evaluate possible effects on quality of life and treatment burden in future clinical studies.
Establish analytical validity, clinical validity and clinical utility before any use in care.
Clinical benefit remains to be demonstrated. Recanthia currently develops research services and does not provide treatment or dosing recommendations.
A future health-economic study would compare outcomes and resource use, with actual treatment pathways and an appropriate comparator.
Separate the published tariff from actual net acquisition costs and the duration of treatment.
Account for preparation, infusion, monitoring and professional time.
Measure the resources used to prevent, monitor and manage adverse events.
Identify hospital stays, consultations and other care without counting the same resource twice.
These are distinct cost categories to measure. No reduction in resource use or healthcare expenditure has yet been demonstrated for Recanthia.
The effects beyond direct medical costs also need to be studied, from the perspective of each person or organisation concerned.
Study work absence and lost working time using a defined method and time horizon.
Document expenses actually borne by patients and families, separately from reimbursed care.
Examine absence, replacement and workplace adjustments from the employer’s perspective.
These perspectives must not be added together without addressing overlaps. No societal saving is claimed at this stage.
08 / Development & innovation
Applications and conversations that support the next stage of the project.
The application has been submitted. Final panel on 20 November 2026; results announced by the organiser on 1 December 2026.
Application to Eurasanté’s We.Pulse support programme in preparation, with its presentation video.
Status at 10 November 2026, as reported by the founders; dates from the organisers’ pages. These are application milestones: no award, admission or funding is claimed.
We are seeking pilot partners, well-characterised cohorts, introductions and funding to build the evidence and prepare our B2B services. Funding needs and their allocation are available through a direct discussion.
09 / Partner with us
Tell us how you would like to contribute. Each button opens a pre-filled email draft.
Bring a candidate, dataset or biological question. Let’s explore a focused research collaboration.
Discuss an R&D projectHelp connect molecular findings with clinical reality through well-characterised cohorts and independent validation.
Propose a collaborationSupport the next milestones: B2B pilots, independent validation and the preparation of future clinical development.
Talk about funding10 / News
We are preparing exploratory projects on therapeutic response in oncology, starting with breast cancer. We welcome conversations with teams developing candidate therapies or studying response in tumour cohorts.
Feasibility
Four questions to prepare a structured first email. Nothing is stored on this site: the button opens a draft in your email application.
11 / Contact
Tell us what decision you are trying to make and what kind of data you have. We will discuss the scope and the evidence a project could deliver.
Direct email[email protected]
